References of "Magné, Julien"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailESC working group on valvular heart disease position paper-heart valve clinics: organization, structure, and experiences
LANCELLOTTI, Patrizio ULg; Rosenhek, R; Pibarot, P et al

in European Heart Journal (2013)

Detailed reference viewed: 46 (9 ULg)
Full Text
Peer Reviewed
See detailSystemic Active and Total Myeloperoxidase Levels in Coronary Artery Disease.
GACH, Olivier ULg; MAGNE, Julien ULg; Franck, Thierry ULg et al

in Cardiology (2013), 126(Suppl. 2), 1-521

Backgound: Measurement of total Myeloperoxidase (MPO) by ELISA is considered as a marker of neutrophil activation but is not the true indicator of the degree of its activity. In a dynamic pathology such ... [more ▼]

Backgound: Measurement of total Myeloperoxidase (MPO) by ELISA is considered as a marker of neutrophil activation but is not the true indicator of the degree of its activity. In a dynamic pathology such as atherosclerosis, it may be important to measure the real active part of MPO because it represents the true witness of the oxidant potential of the enzyme. Aim: To identify the relation between coronary artery disease identified by coronaro-angiography on measured serum total and active MPO levels and evaluate the correlation between these MPO levels and the presence of clinically defined unstable condition. Methods: Prospective analyse of serum samples of patients before (within 30 min) coronaro-angiography. Total and active MPO concentrations were assessed by sandwich Elisa and SIEFED® method’s respectively. Results: Two hundred and twenty patients were included in this study (age: 66.1±10.7 years, 67% of male). Among these, 62% presented significant coronary artery disease (stenosis more than 60% at least in one épicardial coronary artery). Twenty four patients (11%) presented unstable coronary syndrome. Mean active and total MPO in the general population were 50.1±63.5 and 147.6±223.3 ng.mL-1 respectively. In comparison, mean active MPO was 47.1±47.9 ng.mL-1 in stable patients and 75.1±135.2 ng.mL-1 in unstable patients (p=0.04). Mean total MPO was 146.3±224.7 ng.mL-1 in stable patients and 158.2±215.8 ng.mL-1 in the unstable’s one (p=0.8). There was a significant correlation between active MPO levels and instability (r=0.14, p=0.04) not present for total MPO levels (r=0.016, p=0.8). Conclusion: We observed a correlation between active MPO and clinical instability while there was no correlation with total MPO. Our preliminary results suggest that this marker could be a powerful indicator of instability which could possess an important prognostic impact. This hypothesis requires an evaluation in wider population and during a prolonged follow-up. [less ▲]

Detailed reference viewed: 24 (1 ULg)
Full Text
Peer Reviewed
See detailStress echocardiography and mitral valvular heart disease.
Magne, Julien ULg; LANCELLOTTI, Patrizio ULg; Pierard, Luc ULg

in Cardiology Clinics (2013), 31(2), 311-21

The European Society of Cardiology's updated guidelines emphasize the usefulness of exercise stress echocardiography in patients with valvular heart disease. Exercise-induced changes in valve hemodynamics ... [more ▼]

The European Society of Cardiology's updated guidelines emphasize the usefulness of exercise stress echocardiography in patients with valvular heart disease. Exercise-induced changes in valve hemodynamics should be assessed in patients with mitral valve disease. In asymptomatic patients with moderate or severe mitral regurgitation without left ventricular dysfunction/dilatation, exercise stress echocardiography may identify a subset of patients with reduced cardiac event-free survival who are at a higher risk of developing symptoms. In patients with mitral stenosis who are asymptomatic, the development of symptoms during exercise is strongly related to the kinetics of the changes in the systolic pulmonary arterial pressure. [less ▲]

Detailed reference viewed: 23 (4 ULg)
Full Text
Peer Reviewed
See detailNormal Reference Ranges for Echocardiography: rationale, study design, and methodology (NORRE Study).
LANCELLOTTI, Patrizio ULg; Badano, Luigi P.; Lang, Roberto M. et al

in European Heart Journal - Cardiovascular Imaging (2013), 14(4), 303-8

BACKGROUND: Availability of normative reference values for cardiac chamber dimensions, volumes, mass, and function is a prerequisite for the accurate application of echocardiography for both clinical and ... [more ▼]

BACKGROUND: Availability of normative reference values for cardiac chamber dimensions, volumes, mass, and function is a prerequisite for the accurate application of echocardiography for both clinical and research purposes. However, due to the lack of consistency in current echocardiographic 'reference values', their use for clinical decision-making remains questionable. AIMS: The aim of the 'Normal Reference Ranges for Echocardiography Study (NORRE Study)' is to obtain a set of 'normal values' for cardiac chamber geometry and function in a large cohort of healthy Caucasian individuals aged over a wide range of ages (25-75 years) using both conventional and advanced echocardiographic techniques. METHODS: The NORRE Study is a large prospective, observational multicentre study in which transthoracic echocardiographic studies will be acquired in 22 laboratories accredited by the European Association of Cardiovascular Imaging and in one laboratory in the USA accredited by ICAEL. The final sample size has been estimated in 1100 normal subjects in whom M-mode, 2D, and 3D imaging, colour Doppler, pulsed-wave Doppler, pulsed-wave tissue Doppler, and colour tissue Doppler imaging data will be obtained. All studies will be sent to a central echocardiographic core laboratory for quantitative analysis. Multiple studies will be performed for reproducibility analysis. CONCLUSION: After completion of the NORRE Study, uniform reference limits according to age, gender, and anthropometric parameters will be available to standardize the quantitative interpretation of echocardiography. [less ▲]

Detailed reference viewed: 14 (2 ULg)
Full Text
See detailA prospective study of cardiac valvular status in patients treated with cabergoline for endocrine disease
VROONEN, Laurent ULg; LANCELLOTTI, Patrizio ULg; Tome, M et al

in Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013)

Detailed reference viewed: 23 (3 ULg)
Full Text
Peer Reviewed
See detailHemodynamic comparison of restrictive mitral valve annuloplasty and mitral valve replacement for ischemic mitral regurgitation
Fino, C; Iacovoni, a; Ferrero, P et al

in Circulation (2013)

Detailed reference viewed: 20 (4 ULg)
Full Text
Peer Reviewed
See detailEuroEcho and other imaging modalities: highlights
LANCELLOTTI, Patrizio ULg; Magne, Julien ULg; Sicari, R et al

in European Journal of Echocardiography (2013)

Detailed reference viewed: 5 (2 ULg)
Full Text
Peer Reviewed
See detailImpact of hemodynamic load on exercise capacity in aortic stenosis
Dulgheru, Raluca Elena ULg; Magne, Julien ULg; Capoulade, R et al

in International Journal of Cardiology (2013)

Detailed reference viewed: 58 (6 ULg)
Full Text
Peer Reviewed
See detailLeft ventricular contractile reserve in asymptomatic primary mitral regurgitation
Magne, Julien ULg; Mahjoub, H; PIERARD, Luc ULg et al

in European Heart Journal (2013)

Detailed reference viewed: 22 (5 ULg)
Full Text
Peer Reviewed
See detailnon invasive estimation of left atrial pressure and mitral valve area waveforms during an entire cardiac cycle
Paeme, Sabine ULg; Pironet, Antoine ULg; LANCELLOTTI, Patrizio ULg et al

in proceeding of 11th national day of the National Committee on Biomedical Engineering (2012, December 07)

Detailed reference viewed: 18 (3 ULg)
Full Text
See detailSeguimiento prospectivo ecocardiografico de 104 pacientes con enffermedades endocrinologicas tratados con cabergolina
Daly, Adrian ULg; VROONEN, Laurent ULg; Lancellotti, Patrizio ULg et al

in Abstract book - 54 Congreso Sociedad Espanola de Endocrinologia y nutrition (2012, May 23)

Detailed reference viewed: 10 (0 ULg)
Full Text
See detailA prospective study of cardiac valvular status in patients treated with cabergoline for Endocrine Disease
VROONEN, Laurent ULg; LANCELLOTTI, Patrizio ULg; TOME, M et al

in Endocrine abstracts - May 2012, volume 29 (2012, May)

Detailed reference viewed: 17 (5 ULg)
Full Text
Peer Reviewed
See detailA prospective study of cardiac valvular status in patients treated with cabergoline for Endocrine Disease
VROONEN, Laurent ULg; Lancellotti, Patrizio ULg; Tome Garcia, M et al

in Annales d'Endocrinologie (2012, April), 73(2), 148

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailClinical outcome in asymptomatic severe aortic stenosis: Insights from the new proposed aortic stenosis grading classification
Lancellotti, Patrizio ULg; Magne, Julien ULg; Donal, E. et al

in Journal of the American College of Cardiology (2012), 59(3), 235-243

Detailed reference viewed: 16 (3 ULg)
Full Text
Peer Reviewed
See detailRisk stratification in asymptomatic aortic stenosis
Dulgheru, R.; Weisz, S. H.; Magne, Julien ULg et al

in European Cardiology (2012), 8(2), 120-124

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailPrognostic importance of exercise brain natriuretic peptide in asymptomatic degenerative mitral regurgitation
Magne, Julien ULg; Mahjoub, H.; Pibarot, P. et al

in European Journal of Heart Failure (2012), 14(11), 1293-1302

Detailed reference viewed: 27 (10 ULg)
Full Text
Peer Reviewed
See detailImpact of aortic stenosis severity and its interaction with prosthesis-patient mismatch on operative mortality following aortic valve replacement.
Girerd, N.; Dumesnil, J. G.; Magne, Julien ULg et al

in Journal of Heart Valve Disease (The) (2012), 21(2), 158-167

Detailed reference viewed: 15 (3 ULg)